Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Conference News THT 2026

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

Todd Neale

March 05, 2026

News Daily News

CV Screening, Care at UK Football Club Made Inroads Against HF

Caitlin E. Cox

March 07, 2025

Presentation THT Abstracts 2024

Long-Term Quality of Life Response Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Presenter: JoAnn Lindenfeld

March 04, 2024

Presentation THT Abstracts 2024

Utilization of Advanced Heart Failure Interventions Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Presenter: William Abraham

March 04, 2024

Presentation THT 2024

Utilization of Advanced Heart Failure Interventions Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Presenter: William T. Abraham

March 04, 2024

Presentation THT 2024

Long-Term Quality of Life Response Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Presenter: JoAnn Lindenfeld

March 04, 2024

Presentation THT 2023

Baroreflex Activation Therapy (BAT) in Patients With Heart Failure and a Reduced Ejection Fraction (BeAT-HF): Long-Term Outcomes

Presenter: Michael Zile

March 21, 2023

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Shelley Wood

December 23, 2019

News Daily News

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Todd Neale

August 19, 2019

News Conference News HRS 2019

BeAT-HF: Baroreflex Activation Therapy Improves Outcomes in Subset of HF Patients

Todd Neale

May 15, 2019

News Industry News

CVRx® Announces that the First Two Patients were Treated in the Phase III Pivotal Trial Evaluating BAROSTIM THERAPY® for the Treatment of Heart Failure

June 06, 2016

News Industry News

CVRx® Announces Expedited Access Pathway Designation By FDA for Barostim Therapy® for the Treatment Of Heart Failure In Order To Accelerate Access for US Patients

November 18, 2015

Advertisement

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

CV Screening, Care at UK Football Club Made Inroads Against HF

Long-Term Quality of Life Response Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Utilization of Advanced Heart Failure Interventions Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Utilization of Advanced Heart Failure Interventions Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Long-Term Quality of Life Response Observed in the Baroreflex Activation Therapy for Heart Failure (BeAT-HF) Trial

Baroreflex Activation Therapy (BAT) in Patients With Heart Failure and a Reduced Ejection Fraction (BeAT-HF): Long-Term Outcomes

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

BeAT-HF: Baroreflex Activation Therapy Improves Outcomes in Subset of HF Patients

CVRx® Announces that the First Two Patients were Treated in the Phase III Pivotal Trial Evaluating BAROSTIM THERAPY® for the Treatment of Heart Failure

CVRx® Announces Expedited Access Pathway Designation By FDA for Barostim Therapy® for the Treatment Of Heart Failure In Order To Accelerate Access for US Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content